CymaBay Therapeutics, Inc. (CBAY) Stock Increasing in Aftermarket Despite no Apparent Reason
CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company, has increased 5.47% in aftermarket trading session and consequently was trading at $4.63 at the time of